Blue Jet Healthcare Limited Just Recorded A 7.4% EPS Beat: Here's What Analysts Are Forecasting Next
Blue Jet Healthcare Limited (NSE:BLUEJET) came out with its first-quarter results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report. Blue Jet Healthcare missed revenue estimates by 2.7%, coming in at₹2.9b, although statutory earnings per share (EPS) of ₹4.51 beat expectations, coming in 7.4% ahead of analyst estimates. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Following the latest results, Blue Jet Healthcare's five analysts are now forecasting revenues of ₹12.1b in 2027. This would be a sizeable 36% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to shoot up 34% to ₹16.65. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹11.7b and earnings per share (EPS) of ₹17.33 in 2027. Overall it looks as though the analysts were a bit mixed on the latest results. Although there was a a sizeable to revenue, the consensus also made a minor downgrade to its earnings per share forecasts.
Check out our latest analysis for Blue Jet Healthcare
The analysts also upgraded Blue Jet Healthcare's price target 7.8% to ₹540, implying that the higher revenue expected to generate enough value to offset the forecast decline in earnings. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Blue Jet Healthcare analyst has a price target of ₹680 per share, while the most pessimistic values it at ₹370. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Blue Jet Healthcare's rate of growth is expected to accelerate meaningfully, with the forecast 51% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 14% p.a. over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 12% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Blue Jet Healthcare to grow faster than the wider industry.
The Bottom Line
The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.
With that in mind, we wouldn't be too quick to come to a conclusion on Blue Jet Healthcare. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Blue Jet Healthcare going out to 2029, and you can see them free on our platform here..
You can also see our analysis of Blue Jet Healthcare's Board and CEO remuneration and experience, and whether company insiders have been buying stock.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.